Bedrijfsoverzicht
InterCure Ltd. is a specialized entity within the healthcare sector that engages in the end-to-end development of medical cannabis, encompassing research, cultivation, production, marketing, and distribution of pharmaceutical-grade products for the Israeli and international markets. The company operates specifically within the drug manufacturers sub-industry focused on specialty and generic pharmaceuticals, positioning itself as a key player in the niche therapeutic cannabis space. Currently, the business employs approximately 320 individuals to execute its operations across the value chain, reflecting a mid-sized organizational footprint for a private company. With a market capitalization of $41.72 million, the firm represents a relatively small-cap asset, indicating a lower market valuation compared to established pharmaceutical giants and suggesting that the company is still establishing its market dominance or is in a growth phase where profitability metrics have not yet scaled proportionally to its revenue generation capabilities.
Financiële gezondheid
The financial statements for the trailing twelve months (TTM) show reported revenue of N/A, net income of N/A, and an EBITDA of $-80,619,000. The significant negative EBITDA figure, despite the absence of reported revenue data in the provided metrics, reveals a cost structure characterized by heavy investment in research and cultivation that has not yet translated into profitable operations at the current scale. The company generated a free cash flow of $-18,398,624, which indicates a substantial cash burn rate and limited immediate financial flexibility to fund operations without external capital injections or equity dilution. Margin analysis shows a gross margin of 16.7%, an operating margin of 0.0%, and a profit margin of -29.2%; the wide disparity between gross and profit margins, alongside the zero operating margin, highlights high overhead costs relative to sales that are currently eroding all gross profitability. Regarding liquidity and leverage, the company holds N/A in cash while carrying N/A in debt, resulting in a debt-to-equity ratio of 41.49, which suggests a highly leveraged balance sheet structure where equity is the primary buffer against liabilities. The current ratio stands at 1.85, indicating that the company possesses sufficient current assets to cover its short-term obligations, though this metric does not fully mitigate the impact of the high debt-to-equity leverage on long-term solvency. Return metrics further illustrate operational inefficiencies in generating returns on capital, with a return on equity (ROE) of -16.7% and a return on assets (ROA) of -7.7%, signaling that management is currently unable to generate positive returns on the shareholders' equity or the total asset base utilized.
Waarderingsbeoordeling
Valuation multiples for InterCure Ltd. present a complex picture, with a trailing P/E ratio of N/A and a forward P/E of -0.52. The negative forward P/E ratio implies that analysts or the market expects the company to continue reporting losses in the coming year, as earnings per share are currently negative and projected to remain so in the near term. The price-to-book ratio is recorded at 0.10, indicating that the market values the company at only 10% of its book value, which often occurs with distressed assets or companies expected to face significant restructuring or prolonged periods of unprofitability. Alternative valuation metrics such as price-to-sales and EV/EBITDA are listed as N/A, suggesting that traditional revenue-based or enterprise value multiples are not applicable due to the lack of reported revenue figures and the deep negative earnings profile. Price trading dynamics show a 52-week high of $1.77 and a 52-week low of $0.68; assuming a current trading price near the lower end of this volatility range, the stock is trading significantly below its recent highs, reflecting the market's skepticism regarding the timeline for achieving profitability. The beta value is 0.33, which indicates that the stock's price volatility is substantially lower than that of the broader market, suggesting that investor sentiment towards the company is currently detached from general market movements or that the small market cap limits liquidity and broad participation.
Growth & Income
Revenue growth year-over-year is reported at 3.4%, while earnings growth is listed as N/A due to the absence of positive earnings data. The revenue growth rate is modest, indicating a slow expansion in sales volume or pricing, and since earnings are negative, there is no meaningful earnings growth to compare against, implying that the company is still in the investment phase where top-line growth is the primary objective rather than bottom-line improvement. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute profits to shareholders, as there are no profits to distribute; instead, the firm reinvests all available capital back into the business to fund its research, cultivation, and production initiatives. The overall growth and income profile for InterCure Ltd. is defined by a focus on expanding the pharmaceutical-grade cannabis market share through reinvestment, accepting significant cash burn and negative returns in exchange for potential future market penetration and product development within the specialty drug sector.